**Background**
Endometriosis is a chronic inflammatory condition characterized by the growth of endometrial-like tissue outside the uterus, often leading to severe dysmenorrhea and noncyclic pelvic pain. This condition significantly impacts the quality of life for women and requires effective hormonal management to suppress symptom progression and manage pain. Research into hormonal therapies is crucial for developing cost-effective treatments with minimal side effects. In this context, we will introduce a female hormone used for the research of endometriosis – Norethindrone.
**Definition**
Norethindrone acetate is a female hormone and a click chemistry reagent containing an Alkyne group, which allows it to undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups. According to the Norethindrone technical information, it has a molecular weight of 340.46 and a chemical formula of C22H28O3.
**In Vitro and In Vivo Studies**
The Norethindrone biological activity has been extensively studied across various models. Norethindrone in vitro studies using isolated hepatocytes from fed rats demonstrated that Norethindrone acetate (0.1 mM) significantly inhibits the incorporation of both palmitate and glycerol into triglycerides. In vivo studies have shown that Norethindrone acetate serves as a cost-effective alternative for treating symptomatic endometriosis, providing relief from dysmenorrhea and noncyclic pelvic pain. It is a well-tolerated option for managing pain and bleeding across all stages of endometriosis, with improved bleeding scores regardless of prior hormonal regimens. Furthermore, pain scores improved in most patients, except those previously prescribed GnRH-agonist plus add-back.
Toxicological evaluations indicate that Norethindrone acetate exhibits low acute toxicity in experimental animals. Administration to rodents at several multiples of the human dose resulted in no treatment-related mortality, hematological changes, behavioral changes, or organ pathology. Additionally, in rats fed a high carbohydrate diet, administration led to significant and proportional reductions in the concentrations of triglycerides, cholesterol, and phospholipids of plasma lipoproteins of density <1.006. In conclusion, Norethindrone is an effective hormonal agent for the management of endometriosis symptoms and the study of lipid metabolism.
Keywords
Norethindrone, 51-98-9, 19-Norethindrone, Progesterone Receptor, NR3C3, Inhibitor, inhibitor, inhibit
References
[1] Muneyyirci-Delale O, et al. Effect of norethindrone acetate in the treatment of symptomatic endometriosis. Int J Fertil Womens Med. 1998 Jan-Feb;43(1):24-7.
[2] Kaser DJ, et al. Use of norethindrone acetate alone for postoperative suppression of endometriosis symptoms. J Pediatr Adolesc Gynecol. 2012 Apr;25(2):105-8.
[3] Maier WE, et al. Pharmacology and toxicology of ethinyl estradiol and norethindrone acetate in experimental animals. Regul Toxicol Pharmacol. 2001 Aug;34(1):53-61.
[4] Cheng DC, et al. Norethindrone acetate inhibition of triglyceride synthesis and release by rat hepatocytes. Atherosclerosis. 1983 Jan;46(1):41-8.